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ABSTRACT
Introduction: The rapid worldwide spread of
carbapenem-resistant Enterobacteriaceae (CRE)
constitutes a major challenge. The aim of the EUropean
prospective cohort study on Enterobacteriaceae
showing REsistance to CArbapenems (EURECA), which
is part of the Innovative Medicines Initiative Joint
Undertaking (IMI JU) funded COMBACTE-CARE project,
is to investigate risk factors for and outcome
determinants of CRE infections to inform randomised
clinical trial designs and to provide a historical cohort
that could eventually be used for future comparisons
with new drugs targeting CRE.
Methods: A multicentre (50 sites), multinational
(11 European countries), analytical observational
project was designed, comprising 3 studies. The aims
of study 1 (a prospective cohort study) include
characterising the features, clinical management and
outcomes of hospitalised patients with intra-abdominal
infection, pneumonia, complicated urinary tract
infections and bloodstream infections caused by CRE
(202 patients in each group). The main outcomes will
be 30-day all-cause mortality and clinical response.
Study 2 (a nested case–control study) will identify
the risk factors for target infections caused by CRE;
248 selected patients from study 1 will be matched
with patients with carbapenem-susceptible
Enterobacteriaceae (1:1) and with hospitalised patients
(1:3) and will provide a historical cohort of patients
with CRE infections. Study 3 (a matched cohort study)
will follow patients in study 2 in order to assess
mortality, length of stay and hospital costs associated
with CRE. All patients will be followed for 30 days.
Different, up-to-date statistical methods will be applied
to come to unbiased estimates for all 3 studies.
Ethics and dissemination: Before-study sites will be
initiated, approval will be sought from appropriate
regulatory agencies and local Ethics Committees of
Research or Institutional Review Boards (IRBs) to
conduct the study in accordance with regulatory
requirements. This is an observational study and
therefore no intervention in the diagnosis, management
or treatment of the patients will be required on behalf
of the investigation. Any formal presentation or
publication of data collected from this study will be
considered as a joint publication by the participating
physician(s) and will follow the recommendations of
the International Committee of Medical Journal Editors
(ICMJE) for authorship.
Trial registration number: NCT02709408.
Strengths and limitations of this study
▪ The EUropean prospective cohort study on
Enterobacteriaceae showing REsistance to
CArbapenems (EURECA) is a prospective, multi-
national (11 European countries), multicentre
(50 sites) study with onsite investigators collect-
ing a magnitude of reliable information on indi-
vidual level as well as hospital level to reliably
characterise risk factors, clinical management,
best available therapy (BAT) and outcomes of
hospitalised patients with four different types of
infections caused by carbapenem-resistant
Enterobacteriaceae (CRE).
▪ It will also provide a historical cohort treated
with the BAT, enabling inferiority trials as well as
historically controlled superiority trials.
▪ Different up-to-date statistical methods will be
applied to come to unbiased estimates for the
three studies that EURECA includes.
▪ This study has limitations, including its mainly
observational nature, so an impact of unmeas-
ured variables and residual confounding cannot
be discarded. Also, despite the fact that this will
be, to the best of our knowledge, one of the
biggest cohort of patients with infections caused
by CRE, the statistical power in some strata may
be limited.
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INTRODUCTION
Antibiotic resistance is recognised as an important global
public health concern.1 Among antibiotic-resistant organ-
isms, carbapenem-resistant Enterobacteriaceae (CRE) have
spread rapidly worldwide and now present a major chal-
lenge for treating patients suffering from infections
caused by them. Resistance to carbapenems can be
mediated by different mechanisms, although the produc-
tion of carbapenemases (β-lactamases with hydrolytic
activity against carbapenems) is the most worrisome
because of their recent dramatic spread in many coun-
tries.2 Unfortunately, carbapenemase-producing
Enterobacteriaceae (CPE) are frequently resistant to other
antibiotic families, which considerably limits the available
therapeutic options against them.
Until now, little is known on several aspects of infec-
tions due to CRE and/or CPE. First, although a
meta-analysis showed that infections caused by CRE were
associated with higher mortality rates than those caused
by carbapenem-susceptible isolates,3 the studies provid-
ing the primary data had methodological limitations
such as insufﬁcient control for confounders. Second,
most of the studies investigating the clinical impact and
outcome of these infections were carried out in speciﬁc
environments (such as intensive care units (ICUs) or
outbreaks), or included only speciﬁc types of infection.
Third, the management patterns in different settings
and their impact on clinical outcomes were not deﬁned.
Fourth, the currently recommended therapy (use of at
least two active drugs, including at least one carbapenem
if the minimum inhibitory concentration (MIC) of these
drugs is sufﬁciently low)4 is based only on retrospective
studies, which mostly included bacteraemic infections
caused by Klebsiella pneumoniae carbapenemase
(KPC)-producing Klebsiella pneumoniae.5–7 As a result, the
best available therapy (BAT) is not well deﬁned for dif-
ferent organisms or clinical situations. These issues are
important in order to evaluate medical needs in this
area and to design randomised controlled trials with
newer and older drugs.
Performing randomised trials can be particularly difﬁ-
cult in the case of multidrug-resistant organisms
(MDRO), because patients cannot be selectively
recruited before microbiological results are available
and empirical treatment can dilute the impact of the
drugs under study. Historical control groups have been
viewed as an option for providing rapid real-world data
on the efﬁcacy of anti-infectives speciﬁcally in the case
of serious infections with poor outcomes and limited
treatment options, like those caused by CRE.8 To be
useful for such purposes, the historical cohort should
include all known confounders of the effect, use consist-
ent exposure and outcome deﬁnitions, and data quality
should be ensured.
The EUropean prospective cohort study on
Enterobacteriaceae showing REsistance to CArbapenems
(EURECA), which is part of the Innovative Medicines
Initiative Joint Undertaking (IMI JU)-funded
COMBACTE-CARE project,9 aims to clarify some of the
above gaps and to support regulatory pathways for new
antibiotics.10 The main objectives of EURECA are: (1) to
identify the predictors for negative outcomes in patients
with intra-abdominal infection (IAI), pneumonia, com-
plicated urinary tract infections (cUTI) and bloodstream
infections (BSI) caused by CRE, including the impact of
clinical management and different antimicrobial regi-
mens on outcome and identiﬁcation of the BAT; (2) to
identify the risk factors for the aforementioned infec-
tions caused by CRE; (3) to provide cohorts of patients
with the target infections caused by CRE that could
eventually be used as historical cohorts for making com-
parisons of the efﬁcacy and safety of other drugs against
CRE organisms; and (4) to assess the mortality, length of
hospital stay and hospitalisation costs associated with the
target infections caused by CRE.
METHODS AND ANALYSIS
Studies and design
To answer the above questions, a prospective, multi-
national, multicentre, analytical observational project
was designed that included three substudies (ﬁgure 1).
The study designs are:
Study 1: To achieve objectives 1 and 3, a prospective
cohort study will be carried out comprising patients with
targeted infections due to CRE.
Study 2: To achieve objective 2, a matched nested
case–control study will be performed. Cases will be
selected from study 1. The ﬁrst group of matched con-
trols will be selected among patients with infections
caused by carbapenem-susceptible Enterobacteriaceae
(CSE), and the second group of matched controls will
comprise admitted patients without CRE infection
(admitted patients).
Study 3: To achieve objective 4, a matched cohort
study will be conducted. Cohorts will comprise patients
with infections due to CRE, patients with infections due
to CSE and ‘admitted patients’ included in study 2.
Sites and study period
The study will be performed in 50 hospitals throughout
countries in southern Europe including Albania,
Croatia, Greece, Italy, Kosovo, Montenegro, Romania,
Serbia, Spain and Turkey. The participating sites were
Figure 1 Study design according to targeted objectives.
BAT, best available therapy; CRE, carbapenem-resistant
Enterobacteriaceae; CSE, carbapenem-susceptible
Enterobacteriaceae.
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selected after completing speciﬁc feasibility question-
naires that included data on rates of infection due to
CRE, number of beds for adult and paediatric patients,
clinical and laboratory capabilities and experience in
clinical studies.
All consecutive patients with IAI, pneumonia, cUTI
and BSI due to CRE diagnosed at the participating hos-
pitals (202 patients in each group) will be eligible.
These patients will be identiﬁed daily by reviewing local
microbiological laboratory reports at each site. Each
patient with any Enterobacteriaceae isolate fulﬁlling the
microbiological criteria for CRE (see below) taken from
a clinical sample (screening samples will not be consid-
ered) will be evaluated for inclusion and exclusion cri-
teria. These patients will form the CRE cohorts in study
1; 248 of these patients will be selected to serve as the
CRE case group in study 2 and the CRE cohort in study
3 (ﬁgure 2).
For each CRE case patient, one patient will be included
from whom CSE has been isolated; CSE controls will be
matched by centre, type of acquisition (community or
nosocomial), type of hospital service, length of hospital-
isation before infection and type of infection. These
patients will serve as the matched CSE control group of
study 2 and the matched CSE cohort of study 3.
Finally, for each CRE case patient, three admitted
patients without Enterobacteriaceae infection will be
included matched to the corresponding CRE case by
centre, ward and length of hospitalisation. These
patients will serve as the matched admitted patient
controls in study 2, and as the matched ‘admitted
patient’ cohort in study 3.
All patients will be followed for a period of 30 days
after inclusion. A summary of the three key visits during
follow-up is shown in table 1.
Inclusion criteria for CRE patients
▸ CRE is isolated from a clinical sample (eg, a sample
obtained in the work-up of a patient with suspicion of
infection; hence, screening samples will not be
considered).
▸ The patient meets the criteria for any of the following
infections (see deﬁnitions below): cUTI, pneumonia,
IAI or BSI.
▸ The patient or his/her representative has signed an
informed consent form if requested by the local
Institutional Review Board (IRB).
Exclusion criteria for CRE patients
▸ The infection is considered to be polymicrobial
according to standard microbiological interpretations
of culture results (except for IAI, in which polymicro-
bial infections are allowed).
▸ The patient is participating in a clinical trial that
involves active treatment for these infections.
▸ The patient was previously included in the same
cohort of this study for the same organism. A single
episode of CRE per patient may be included.
▸ Patients with do-not-resuscitate orders or with a life
expectancy of <30 days.
Figure 2 Decision tree for patient enrolment. BSI, blood stream infection; CRE, carbapenem-resistant Enterobacteriaceae;
CSE, carbapenem-susceptible Enterobacteriaceae; cUTI, complicated urinary tract infection; eCRF, electronic case report form;
IAI, intra-abdominal infection; PN, pneumonia.
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Study variables
The primary end points for study 1 are 30-day all-cause
mortality and clinical response at day 21 (test-of-cure,
TOC), categorised as failure versus cure/improvement.
The secondary end points are: microbiological response
at TOC, mortality during hospitalisation, infection-
related mortality until day 21, length of hospital stay
after infection, length of ICU stay (if appropriate), dur-
ation of antibiotic treatment, recurrence, superinfection
and therapy-related adverse events.
The primary end point for study 2 is infection due to
CRE. The primary end points for study 3 are 30-day all-
cause mortality, length of hospital stay after infection,
length of ICU stay and duration of mechanical ventila-
tion, if appropriate.
The following explanatory variables will be collected:
age, gender, date of admission, ethnicity, country, hos-
pital, type of hospital ward, recent travel abroad, contact
with pets or livestock, profession, contact with persons
colonised by CRE during previous hospitalisations in an
acute care hospital or long-term care facility, previous
colonisation by CRE, comorbidities (type and severity
according to the Charlson index for adults11 and
Antibiotic Resistance and Prescribing in European
Children (ARPEC) Point Prevalence Survey (ARPEC
PPS) deﬁnitions for children),12 transplantation, neutro-
paenia, use of immunosuppressive drugs, HIV infection
with <200 CD4 cells/mm3 type of acquisition (nosoco-
mial, healthcare-associated or community),13 14 severity
of sepsis,15 16 Pitt score,17 Sepsis-related Organ Failure
Assessment (SOFA) and QuickSOFA scores,18 19
Pediatric Early Warning Score (PEWS) score in chil-
dren,20 Acute Physiology And Chronic Health
Evaluation II (APACHE II) score in ICU patients,21
Pediatric Index of Mortality 2 (PIM2)2 in children
admitted to the ICU,22 invasive procedures (mechanical
ventilation, central venous catheter, urinary catheter,
surgery), type of infection, microbiological features of
the isolate (carbapenemase producer or not, carbapene-
mase type, susceptibility proﬁle, carbapenem MICs),
clinical management other than antimicrobial therapy
(source control, support therapy), antimicrobial therapy
(including all antibiotics administered, dose, start and
discontinuation dates, reason/s for discontinuation) and
adverse events related to antimicrobial therapy (renal
toxicity, liver toxicity, Clostridium difﬁcile infection).
Definitions
The deﬁnitions of cUTI, pneumonia, IAI and BSI are
shown in table 2. For the purpose of the study, a CRE is
deﬁned as any isolate identiﬁed as an Enterobacteriaceae
showing a MIC of meropenem or imipenem of ≥1 mg/L
if using any dilution method, and/or of ≤22 mm if
using a disk-diffusion method (10 µg disks). A CSE is
deﬁned as any isolate identiﬁed as an Enterobacteriaceae
showing susceptibility to carbapenems according to the
above criteria. Meropenem-susceptible and imipenem-
susceptible isolates showing resistance to ertapenem will
be excluded.
Microbiological studies
Local laboratories will identify the isolates and perform
routine susceptibility testing according to standard
microbiological procedures; also, CRE isolates will be
studied locally using the CARBA NP test. All CRE iso-
lates will be preserved at −20°C and sent to a central
laboratory for detection and characterisation of carbape-
nemase genes.
Sample size
The sample size for the CRE has been calculated in a
way that the cohorts can serve as ‘historical’ cohorts in
future comparisons involving other drugs against CRE
infections. To do this, and because the estimate for the
outcome variable of the new drug is unknown, we seek
to generate clinical cure rate estimates for the BAT with
95% CI and 8% precision. For an estimated cure rate of
50%, based on data from previous studies,5–7 151
patients with each type of infection (cUTI, pneumonia,
IAI and BSI) are needed. However, since ∼25% of
patients will not receive the BAT, 201 patients per type
of infection will be included. This sample size will also
Table 1 Simplified follow-up schedule and variables to be collected
Variables Day 0 From day 0 to 21 Day 21 (TOC) Day 30 (end of follow-up)
Selection criteria √
Demographics √
Risk factors √
Comorbidities √
Clinical features √ √ √
Microbiology √
Antimicrobial therapy √ √ √ √
Non-antibiotic treatment √ √ √ √
Outcome √ √
Other analytical results √ √ √
Safety of drugs √ √ √ √
TOC, test-of-cure.
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Table 2 Definitions of infections included in the study
Type of infection Definition
Complicated
urinary tract
infection
For adults and children >12 years (any of them)
A positive blood culture for CRE or CSE
and
One of the following:
One local symptom (urgency, frequency,
dysuria, tenesmus or suprapubic tenderness)
or
Two systemic symptoms or predisposing
conditions (fever (>38°C core or >38.3o C
armpit) or hypothermia (<36oC core), new
cognitive impairment or change in mental status
(in patients over 70 years), flank pain,
costovertebral angle tenderness on physical
examination, urinary tract abnormalities or
presence of a urinary catheter)
or
A positive urine culture (isolation of CRE or
CSE, ≥105 microorganisms per mL of urine)
and
No other recognised cause of the bloodstream
infection
A positive urine culture for CRE or CSE (c)
and
Two systemic symptoms or predisposing conditions (fever (>38 test-of-cure C core or >38.3°C
armpit) or hypothermia (<36oC core), new cognitive impairment or change in mental status (in
patients over 70 years), flank pain, costovertebral angle tenderness on physical examination,
urinary tract abnormalities or presence of a urinary catheter)
and
No other recognised cause of a UTI
For children >2 years
Abnormal urinary dipstick test (leucocyte esterase >1+, or positive nitrite test) or urinalysis (pyuria with at least 10 WCCs per high power field in
centrifuged urine, and bacteriuria with any bacteria per high power field on an unstained specimen of urinary sediment)
and
At least two of the following clinical or biological signs:
1. Fever with temperature of 38°C or higher
2. Abdominal or flank pain, urgency, frequency, dysuria, suprapubic tenderness
3. Elevated C reactive protein or procalcitonin concentrations, according to the local laboratory
and
A positive urine culture with isolation of CRE or CSE only (spontaneously voided urine with≥105 microorganisms per mL of urine or suprapubic
aspirate/urinary catheter with ≥104 microorganisms per mL of urine) or a positive blood culture with isolation of CRE with no other recognised cause
For children ≤2 years old
Abnormal urinary dipstick test (leucocyte esterase >1+ or positive nitrite test) or urinalysis (pyuria with at least 10 WCCs per high power field in
centrifuged urine, and bacteriuria with any bacteria per high power field on an unstained specimen of urinary sediment)
and
At least two of the following clinical or biological signs:
1. Fever with temperature of 38°C or higher
2. General, non-specific signs such as irritability, vomiting, diarrhoea or feeding problems in infants
3. Elevated C reactive protein or procalcitonin concentrations according to the local laboratory
and
Continued
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Table 2 Continued
Type of infection Definition
A positive urine culture with isolation of CRE or CSE only (spontaneously voided urine with ≥Ab 105 microorganisms per mL of urine or suprapubic
aspirate/urinary catheter with≥104 microorganisms per mL of urine) or positive blood culture with isolation of CRE with no other recognised cause
Intra-abdominal
infection
For all age groups (either of them)
Patient has organisms cultured from purulent
material from intra-abdominal space obtained
during a surgical operation or needle aspiration.
Patient has at least two of the following signs or symptoms with no other recognised cause:
1. Fever (>38°C)
2. Nausea
3. Vomiting
4. Abdominal pain
5. Jaundice
and
One of the following:
1. Organisms cultured from drainage from surgically placed drain (eg, closed suction drainage
system, open drain, T-tube drain)
2. Organisms cultured from blood and radiographic evidence of infection, for example, abnormal
findings on ultrasound, CT scan, MRI or radiolabelled scans (gallium, technetium, etc) or on
abdominal X-ray
Pneumonia For all age groups (at least one of the following criteria: radiological, clinical and microbiological)
Radiology Clinical criteria Microbiology
Chest X-rays or CT scan with a suggestive
image of pneumonia (for patients with
underlying cardiac or pulmonary disease, a new
infiltrate needs to be demonstrated by comparing
with a previous chest X-ray or CT scan)
For children ≤12 years oldAt least three of
the following:
1. Fever >38°C with no other cause
2. Leucocytosis or leucopaenia (see
age-specific laboratory variables above)
3. Worsening gas exchange (eg, O2
desaturations (eg, pulse oximetry reading
<94%), increased oxygen requirements
or increased ventilator demand)
4. Apnoea, tachypnoea, nasal flaring with
retraction of chest wall or grunting
5. Wheezing, rales or rhonchi
6. Cough
7. Bradycardia or tachycardia (age-specific)
For children ≥12 and adults
At least one each of the following symptoms/
signs/laboratory data:
1. Fever >38°C
2. Leucocytosis (≥12 000 WCC/mm3)
3. Leucopaenia (<4000 WCC/mm3)
4. In patients ≥70 years old, new cognitive
impairment or worsening mental status
and
Isolation of bacteria from any of the following:
1. Quantitative culture from minimally
contaminated lower respiratory tract specimen
(bronchoalveolar lavage (BAL) with a threshold
of >104 CFU/mL or ≥5% of BAL-obtained cells
containing intracellular bacteria on direct
microscopic examination; protected specimen
brush with a threshold of >103 CFU/mL; distal
protected aspirate with a threshold of >103
CFU/mL)
2. Quantitative culture of endotracheal aspirate or
unprotected specimen brush with a threshold
of 106 CFU/mL
3. Blood cultures, not related to any other source
of infection
4. Pleural fluid or needle aspiration of pleural or
pulmonary abscess
5. Sputum culture with quality criteria (>25
leucocytes/field 100X and <10 squamous
epithelial cells/field 100X)
Continued
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be sufﬁcient in order to investigate the BAT with the
merged CRE cohorts (ﬁgure 3).
The CRE case group will comprise 248 patients
selected from those with infections due to CRE. In
order to represent the proportions of different types of
target infection caused by CRE, based on previous
studies,23 24 the ﬁrst 124 (∼50%) patients with cUTI, the
ﬁrst 75 patients (∼30%) with pneumonia, the ﬁrst 25
patients (∼10%) with IAI and the ﬁrst 24 patients
(∼10%) with BSI not included in the previous groups
will be included. For each CRE case, one CSE control
patient and 3 non-infected controls will be selected.
Statistical analysis
The outcomes associated with exposure to different vari-
ables will be compared; targeted exposures will be
empirical active antimicrobial therapy, early targeted
optimised therapy and early source control.
Antimicrobial regimens will be analysed as empirical
(administered before susceptibility testing is available)
and targeted therapy (thereafter). The analysis of end
points will be performed with respect to the respective
type; survival techniques will be used for time-to-event
outcomes, accounting for competing risks; Cox models
will be used for all event-speciﬁc hazards. Clinical or
microbiological response at TOC will be analysed using
logistic regression.
For an analysis of risk factors, CRE cases will be com-
pared with both CSE controls and admitted controls.
The sampling design requires a nested case–control ana-
lysis of the outcome infection due to CRE. Since the
occurrence of infection due to CRE is subject to the
competing risks of death in hospital or live discharge
from hospital with or without CRE infection, the
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Figure 3 Sample size required for each study. CRE,
carbapenem-resistant Enterobacteriaceae; CSE,
carbapenem-susceptible Enterobacteriaceae.
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analyses will be supplemented with those of the compet-
ing outcomes. Multilevel hospital data (local CRE rate,
antimicrobial consumption, infection control measures)
will also be considered in the analyses above.
Mortality, length of hospital and ICU stay, and duration
of mechanical ventilation of patients with CRE, CSE and
admitted patients will be compared. All time-to-event out-
comes will be compared using survival techniques. Extra
hospital/ICU days will be estimated using Beyersmann
et al’s25 multistate approach. Goodness of ﬁt will be
assessed, and variable selection will be based on Akaike’s
information criterion26 throughout.
ETHICAL ISSUES AND DISSEMINATION PLAN
This study will be conducted according to the principles
of the Declaration of Helsinki and in accordance with
the Medical Research Involving Human Subjects Act
(WMO) and local guidelines in the participating coun-
tries. Before-study sites will be initiated, approval will be
sought from appropriate regulatory agencies and local
Ethics Committees of Research or IRBs to conduct the
study in accordance with regulatory requirements. This
is an observational study and therefore no intervention
in the diagnosis, management or treatment of the
patients will be required on behalf of the investigation.
All patient management, including all antibiotic regi-
mens prescribed, will be decided by the physician/team
in charge without any interference. No management
procedures from routine evidence-based management
are included as part of the investigation.
Processing of the patients’ personal data collected in
this study will comply with the Data Protection Act 1998
and the European Directive on the Privacy of Data. All
data collected, stored and processed will be anonymised
(95/46/EC). The principal investigator/lead researcher
at each site will guarantee that all team members or
other persons involved at his site respect the conﬁdenti-
ality of any information concerning the study patients
and ensure that the personal privacy of any patient
whose data are collected in the study is not violated.
Individual written consent of the patient is not
required; however, if any local or central IRB decides
that written informed consent is needed, it will be
required at the speciﬁc sites. Training in research
methods for the study will be provided for all site per-
sonnel involving face-to-face meetings and webcast tele-
conferences. To guarantee data quality and avoid fraud,
the study sites will be monitored and/or audited. The
sponsor or a designated third party will conduct moni-
toring and audit visits.
Spot check monitoring and source data veriﬁcation
will be conducted to identify that patients exist and that
the data entered in the database have been retrieved
from genuine patient ﬁles and transferred correctly. All
site study-related documents, including patient data
source documents, must be made available for monitor-
ing and audit.
Results will be reported at conferences and in peer-
reviewed publications. It is mandatory that any publica-
tion is based on data from the database, analysed as sti-
pulated in the protocol by investigators in agreement
with the sponsor.
Any formal presentation or publication of data col-
lected from this study will be considered as a joint publi-
cation by the participating physician(s) and will follow
the recommendations of the International Committee
of Medical Journal Editors (ICMJE) for authorship.
DISCUSSION
While antimicrobial resistance is recognised as an
important health problem worldwide, it is challenging
to perform high-quality comparative clinical research on
therapeutic options for infections caused by
antimicrobial-resistant bacteria. The reported outcomes
of infections caused by MDROs are usually worse than
those caused by susceptible organisms, but appropriate
control of all relevant confounders is key because
MDROs frequently affect debilitated patients prone to
worse prognoses, and this is especially true for CRE
cases. Appropriateness of therapy, an intermediate vari-
able, should be considered as well, but for CRE cases
the BAT is unknown. Then hospital-level variables can
greatly inﬂuence clinical outcomes as well, and therefore
it is of paramount importance to measure risk factors
and clinical outcomes in different environments: higher
versus lower endemicity, small versus large hospitals,
large infection control bundles versus smaller bundles.
Therefore, EURECA is a prospective, multinational, mul-
ticentre study with onsite investigators collecting a mag-
nitude of reliable information on individual level as well
as hospital level to reliably characterise risk factors, clin-
ical management, BAT and outcomes of hospitalised
patients with four different types of CRE infections.
On the basis of the results of retrospective cohort
studies, mainly including patients with bacteraemic
infections caused by KPC-producing Klebsiella pneumo-
niae, it has been suggested that the use of combination
therapy is superior to monotherapy for severe/invasive
infections caused by CPE.5–7 Nevertheless, the BAT for
different types of infections and different types of
patients in different settings remains ambiguous.
EURECA will be able to inform future clinical trials on
anti-infectives against CRE infections about the BAT.
Moreover, it will enable researchers to efﬁciently include
a high proportion of CRE cases, based on clinical
proﬁle, and to decide on appropriate sample sizes,
based on detailed clinical outcome estimates for differ-
ent settings. It will also provide a historical cohort
treated with the BAT, enabling inferiority trials as well as
historically controlled superiority trials.8
To the best of our knowledge, despite the fact that the
reported mortality rates of patients with infections due
to CRE are frequently high, the clinical pathway is
unclear and evidence of excess mortality is limited.3
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Possible mechanisms responsible for negative outcomes
include delay in active therapy, use of substandard drugs
and/or increased virulence of CRE. However, in
evidence-based medicine, it is crucial to produce reli-
able, actionable information so that quality of care in
these complicated cases can be improved.
In conclusion, EURECA aims to provide actionable
information for the design of randomised control trials
for the treatment of CRE, as well as robust conclusions
for appropriate clinical decision-making until the results
of such trials are available.
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